research use only

Dapivirine (TMC120) Reverse Transcriptase inhibitor

Name: Dapivirine (TMC120)
Brand: Selleck Chemicals
SKU: S2914
Rating: 5 (13 reviews)

Cat.No.S2914

Dapivirine (TMC120) is a non-nucleoside inhibitor for HIV reverse transcriptase with IC50 of 24 nM. It inhibits a broad panel of HIV-1 isolates from different classes, including a wide range of NNRTI-resistant isolates. Phase 3.

Chemical Structure

Molecular Weight: 329.4

Jump to

Quality Control

Batch: S291401 DMSO]34 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 100%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS
Datasheet

100

Related Targets	Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite HIV HCV Protease
Other Reverse Transcriptase Inhibitors	Fangchinoline Salicylanilide 3'-Fluoro-3'-deoxythymidine (Alovudine) Ulonivirine Lersivirine (UK-453061) Bifendate 4-Chloro-2-(trifluoroacetyl)aniline hydrochloride

Chemical Information, Storage & Stability

Molecular Weight	329.4	Formula	C₂₀H₁₉N₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	244767-67-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CC1=CC(=C(C(=C1)C)NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C

Solubility

In vitro
Batch:

DMSO : 34 mg/mL (103.21 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.700mg/ml (5.16mM)	Taking the 1 mL working solution as an example, add 50 μL of 34 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.240mg/ml (0.73mM)	Taking the 1 mL working solution as an example, add 50 μL of 4.8 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	HIV reverse transcriptase 24 nM
In vitro	Dapivirine (TMC120) prevents HIV-induced syncytium formation in the nanomolar range and shows a low cytostatic activity. It apparently blocks HIV-1 infection in the primary cultures at a 10 nM concentration, but secondary cultures reveal that a 100 nM concentration is needed to completely prevent proviral integration. This compound is well tolerated by epithelial cells, T cells, macrophages, and cervical tissue explants with CC50 (50% cytotoxic concentration) of 10 μM to 20 μM. It potently inhibits infection by both X4- and R5-utilizing HIV-1 strains with IC50 of 1.46 nM in cell-based assays. Dapivirine potently inhibits HIV-1BaL infection of human ectocervical explant tissue in a dose-dependent manner, as evaluated by the reduction in both p24 release and provirus content in cultured explants. It inhibits the transmission of virus to permissive T cells in a dose-dependent manner, with an IC50 of 0.1 nM. This compound results in significant inhibition of HIV infection when explants are challenged with virus immediately with IC90 of 100 nM. It is also able to inhibit viral dissemination by migratory cells.
In vivo	Dapivirine (TMC120)-containing gel at vaginal level inhibits cell-associated HIV infection in mice. More placebo (7 of 12) than this compound (3 of 24) gel users had positive vaginal swab results, with white blood cells being the most common finding. It results in Cmax of 715 pg/mL, AUC of 15 ng×h/mL and T1/2 of 89.87 hours in plasma after 14 days post-dose. Mean concentrations of this compound (0.05%) in vaginal fluids collected at the introitus, mid vagina, and cervix are in the range of 62-265 μg/g on day 1.
References	[1] https://pubmed.ncbi.nlm.nih.gov/14693562/ [2] https://pubmed.ncbi.nlm.nih.gov/19029331/ [3] https://pubmed.ncbi.nlm.nih.gov/12853741/ [4] https://pubmed.ncbi.nlm.nih.gov/20574411/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05416021	Active not recruiting	HIV Infections	International Partnership for Microbicides Inc.	August 1 2022	Phase 1
NCT03593655	Completed	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	January 14 2019	Phase 2
NCT03393468	Completed	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	May 10 2018	Phase 1
NCT03239483	Completed	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	October 26 2017	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):